130 related articles for article (PubMed ID: 16481448)
1. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Scherpbier HJ; Bekker V; van Leth F; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2006 Mar; 117(3):e528-36. PubMed ID: 16481448
[TBL] [Abstract][Full Text] [Related]
2. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
3. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
[TBL] [Abstract][Full Text] [Related]
6. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
7. Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.
van Rossum AM; Geelen SP; Hartwig NG; Wolfs TF; Weemaes CM; Scherpbier HJ; van Lochem EG; Hop WC; Schutten M; Osterhaus AD; Burger DM; de Groot R
Clin Infect Dis; 2002 Apr; 34(7):1008-16. PubMed ID: 11880968
[TBL] [Abstract][Full Text] [Related]
8. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
[TBL] [Abstract][Full Text] [Related]
9. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
[TBL] [Abstract][Full Text] [Related]
10. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
11. Impact on weight and height with the use of HAART in HIV-infected children.
Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
[TBL] [Abstract][Full Text] [Related]
12. [Immunological, virological and clinical response in patients infected with HIV after highly active antiviral therapy with nelfinavir: prospective cohort study].
de Alarcón A; Viciana P; Lozano F; Vergara A; Pujol E; Barrera A; Pérez-Guzmán E; Colmenero MA; Hernández-Quero J; Márquez M; de la Torre J; Aliaga L; Suárez I; Gutiérrez-Ravé V; Torres-Tortosa M; Marín J; Valdayo MJ; Milla M;
Enferm Infecc Microbiol Clin; 2003 Dec; 21(10):543-51. PubMed ID: 14642252
[TBL] [Abstract][Full Text] [Related]
13. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
Pediatr Infect Dis J; 2009 Mar; 28(3):246-8. PubMed ID: 19165130
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia.
Janssens B; Raleigh B; Soeung S; Akao K; Te V; Gupta J; Vun MC; Ford N; Nouhin J; Nerrienet E
Pediatrics; 2007 Nov; 120(5):e1134-40. PubMed ID: 17954553
[TBL] [Abstract][Full Text] [Related]
17. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
18. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.
Saez-Llorens X; Violari A; Ndiweni D; Yogev R; Cashat M; Wiznia A; Chittick G; Harris J; Hinkle J; Blum MR; Adda N; Rousseau F;
Pediatrics; 2008 Apr; 121(4):e827-35. PubMed ID: 18332076
[TBL] [Abstract][Full Text] [Related]
20. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
